Quarterly ResultMay 6, 2026, 07:03 AM
Geron Q1 RYTELO Revenue $51.8M; Net Loss $3.6M
AI Summary
Geron Corporation reported Q1 2026 RYTELO net product revenue of $51.8 million, an 8% increase from Q4 2025, and a net loss of $3.6 million, significantly reduced from $19.8 million in Q1 2025. The company reiterated its 2026 RYTELO net product revenue guidance of $220 million to $240 million and total operating expenses of $230 million to $240 million. Geron also strengthened its leadership team with new appointments and ended the quarter with $341 million in cash and marketable securities.
Key Highlights
- Q1 2026 RYTELO net product revenue reached $51.8 million, an 8% increase from Q4 2025.
- Reported Q1 2026 net loss of $3.6 million, or $0.01 per share, down from $19.8 million in Q1 2025.
- Reiterated 2026 RYTELO net product revenue guidance of $220 million to $240 million.
- Reiterated 2026 total operating expenses guidance of $230 million to $240 million.
- Ended Q1 2026 with $341 million in cash, cash equivalents, and marketable securities.
- RYTELO demand grew 6% and ordering accounts increased by 12% in Q1 2026.
- Appointed Timothy Williams as EVP, Chief Legal Officer, and two new Board members.
- Imetelstat included in NCCN Chemotherapy Order Templates for LR-MDS.